Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 101,636 |
|
|||||
| News | - | ||||||
| Day High | 2.48 | Low High |
|||||
| Day Low | 2.40 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| AN2 Therapeutics Inc | ANTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.09 | 3.78% | 2.47 | 19:03:41 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.48 | 2.40 | 2.48 | 2.47 | 2.38 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 701 | 101,636 | $ 2.44 | $ 248,205 | - | 2.36 - 22.22 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:52:52 | 14 | $ 2.47 | USD |
AN2 Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 73.16M | 29.74M | - | 0 | -42.78M | -1.44 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AN2 Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ANTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.98 | 3.00 | 2.36 | 2.57 | 169,862 | -0.51 | -17.11% |
| 1 Month | 3.27 | 3.88 | 2.36 | 3.12 | 455,064 | -0.80 | -24.46% |
| 3 Months | 19.86 | 21.40 | 2.36 | 4.03 | 527,775 | -17.39 | -87.56% |
| 6 Months | 14.60 | 22.22 | 2.36 | 6.40 | 290,800 | -12.13 | -83.08% |
| 1 Year | 8.38 | 22.22 | 2.36 | 7.18 | 184,202 | -5.91 | -70.53% |
| 3 Years | 16.85 | 23.58 | 2.36 | 8.48 | 116,605 | -14.38 | -85.34% |
| 5 Years | 16.85 | 23.58 | 2.36 | 8.48 | 116,605 | -14.38 | -85.34% |
AN2 Therapeutics Description
| AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. |
